Xilio Therapeutics (XLO) Other Working Capital Changes (2020 - 2026)

Xilio Therapeutics (XLO) has 6 years of Other Working Capital Changes data on file, last reported at -$278000.0 in Q1 2025.

• For the quarter ending Q1 2025, Other Working Capital Changes fell 13.93% year-over-year to -$278000.0; the trailing twelve-month figure through Mar 2025 stood at -$1.1 million (down 13.91% YoY), and the FY2024 full-year result was -$1.0 million, down 14.05% from the prior year.
• Other Working Capital Changes retreated to -$278000.0 in Q1 2025, from -$273000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $46.2 million in Q1 2025 to a low of -$49.3 million in Q2 2025.
• A 5-year average of $1.7 million and a median of $500000.0 in 2025 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes soared 36.71% in 2021 and plunged 516.67% in 2022, its largest moves.
• Tracing XLO's Other Working Capital Changes over 5 years: stood at -$181000.0 in 2021, then dropped by 16.02% to -$210000.0 in 2022, then fell by 13.81% to -$239000.0 in 2023, then slipped by 14.23% to -$273000.0 in 2024, then declined by 1.83% to -$278000.0 in 2025.
• Business Quant data shows XLO's Other Working Capital Changes at -$278000.0 in Q1 2025, -$273000.0 in Q4 2024, and -$267000.0 in Q3 2024.